Deep Dives into Peptide Science
Research breakdowns, protocol design, and the latest findings from the world of peptide science. Written for researchers who care about the evidence.
Mazdutide Cut Weight by 18.1% in a U.S. Trial. The 20% Dropout Rate Matters.
A new U.S. phase 2 trial found dose-dependent weight loss with mazdutide, but the strongest dose also produced a 20% adverse-event dropout rate.
Retatrutide Cut ApoB by 24%. That Is Not the Same as Preventing Heart Attacks
A new analysis found broad reductions in apoB, LDL particles, triglyceride-rich particles, and inflammation. The cardiovascular promise is real, but still rests on biomarkers.
VCT220 Cut Weight by 9.7% in 16 Weeks. The Titration Data Matter More Than the Pill
A 250-person phase II trial found up to 9.73% average weight loss in 16 weeks. The stronger lesson may be how sharply titration speed changed GI side effects.
A 2.5 mg Tirzepatide Dose Matched 5 mg in a New Study. It Does Not Rewrite the Label.
A prospective Japanese cohort found similar six-month weight loss on 2.5 mg and 5 mg tirzepatide. The result is intriguing, but it does not prove dose equivalence or change the US label.
Zenagamtide Worked as a Pill and a Weekly Injection. The Trade-Off Was Tolerability
Two Lancet phase 2 studies tested zenagamtide as a daily pill and weekly injection. Both lowered HbA1c, but high-dose tolerability complicates the headline.
Can Tirzepatide Spare More Muscle? Roche’s Emugrobart Trial Is About to Give Us a Clue
A 285-person phase 2 trial is testing tirzepatide with emugrobart, an anti-myostatin antibody. Here’s what it may reveal about fat loss, lean mass and the limits of the evidence.
A Peptide Lowered IGF-1 by Up to 50%. Its Phase 2 Program Was Already Dead.
ALXN2420 produced a strong first-human biomarker signal in 101 volunteers. AstraZeneca had already removed its acromegaly program. Here is what the data prove—and what the discontinuation does not.
GLP-1 Drugs Raised Severe Gut-Motility Risk by 37%. The Absolute Risk Stayed Low.
A 626,684-person matched cohort found a 37% higher relative risk of severe constipation, gastroparesis, or obstruction with GLP-1 therapies, but the absolute difference was small.
TE-8105 Could Stretch GLP-1 Injections to Every Two Weeks. The First Human Study Is Not an Efficacy Trial.
TE-8105 lasted about five days in the body and supported biweekly dosing in a 38-person first-human study. The weight-loss signal is not efficacy proof.
LTI-03 Reached Patients With Pulmonary Fibrosis. The Biomarker Signal Is Promising, Not Proof.
The first peer-reviewed patient study of inhaled LTI-03 found acceptable 14-day tolerability and shifts in fibrosis-linked biomarkers. It did not test whether patients breathe better or decline more slowly.
BGM0504 Lowered HbA1c by 2.48 Points. The Semaglutide Comparison Needs Context
A 64-person Phase 2 trial found a 2.48-point HbA1c drop at the highest BGM0504 dose. The signal is real, but claims that it beat semaglutide need context.